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in the human cornea
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d IFN-l limits herpes simplex virus 1 and Zika virus growth in
the human cornea
d SARS-CoV-2 does not replicate in human corneal tissue
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Miner et al. report that type III interferon
(IFN-l) and its receptor (IFNlR1) restrict
herpes simplex virus 1 (HSV-1) and Zika
virus (ZIKV) growth in the human cornea.
Human corneal explants did not support
severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) infection,
even after blockade of the type III IFN
receptor.
Miner et al., 2020, Cell Reports 33, 108339
November 3, 2020 ª 2020 The Authors.
https://doi.org/10.1016/j.celrep.2020.108339 ll
Report
HSV-1 and Zika Virus but Not SARS-CoV-2
Replicate in the Human Cornea and Are
Restricted by Corneal Type III Interferon
Jonathan J. Miner,1,2,3,6,7,* Derek J. Platt,2,6 Cyrus M. Ghaznavi,1 Pallavi Chandra,1 Andrea Santeford,4 Amber M. Menos,1
Zhenyu Dong,4 Erin R. Wang,1 Wei Qian,1 Elysse S. Karozichian,1 Jennifer A. Philips,1,2 and Rajendra S. Apte1,4,5,*
1Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
2Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA
3Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
4Department of Ophthalmology, Washington University School of Medicine, St. Louis, MO 63110, USA
5Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA
6These authors contributed equally
7Lead Contact
*Correspondence: miner@wustl.edu (J.J.M.), apte@wustl.edu (R.S.A.)
https://doi.org/10.1016/j.celrep.2020.108339
SUMMARY
Here, we report our studies of immune-mediated regulation of Zika virus (ZIKV), herpes simplex virus 1 (HSV-
1), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the human cornea. We
find that ZIKV can be transmitted via corneal transplantation in mice. However, in human corneal explants,
we report that ZIKV does not replicate efficiently and that SARS-CoV-2 does not replicate at all. Additionally,
we demonstrate that type III interferon (IFN-l) and its receptor (IFNlR1) are expressed in the corneal epithe-
lium. Treatment of human corneal explants with IFN-l, and treatment of mice with IFN-l eye drops, upregu-
lates antiviral interferon-stimulated genes. In human corneal explants, blockade of IFNlR1 enhances replica-
tion of ZIKV and HSV-1 but not SARS-CoV-2. In addition to an antiviral role for IFNlR1 in the cornea, our
results suggest that the human cornea does not support SARS-CoV-2 infection despite expression of
ACE2, a SARS-CoV-2 receptor, in the human corneal epithelium.
INTRODUCTION
The Zika virus (ZIKV) epidemic and severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) pandemic have led to spec-
ulation that these viruses may, in some cases, enter the body
through the eyes. Other viruses, including herpes simplex virus
1 (HSV-1), are well known to efficiently replicate in the cornea.
Indeed, corneal infection with HSV-1 is a major cause of corneal
damage and vision loss (Farooq and Shukla, 2012). However, the
immunemechanisms that regulate infection of the human cornea
are incompletely understood.
During viral infections, type I and type III interferons (IFNs)
induce expression of IFN-stimulated genes (ISGs) that restrict
viral replication and spread (Hoffmann et al., 2015; Lazear
et al., 2015; Miner et al., 2016a, 2016b). Whereas the type I IFN
receptor (IFNAR1) is expressed ubiquitously, the type III IFN re-
ceptor (IFNlR1; IL28RA) has a more restricted expression
pattern, leading to antiviral effects that are especially notable
at barrier surfaces, including the placenta, gut, urogenital tract,
and blood-brain barrier (Bayer et al., 2016; Jagger et al., 2017;
Lazear et al., 2015; Nice et al., 2015). A role for IFNlR1 signaling
in the human cornea has not previously been described.
HSV-1 infection of the human cornea requires emergency
treatment, including antiviral and corticosteroid therapy to
help prevent corneal opacification and to preserve vision (Far-
ooq and Shukla, 2012). HSV-1 keratitis alone is responsible
for 40,000 new cases of visual impairment and blindness
globally each year (Farooq and Shukla, 2012). Other viruses,
including flaviviruses (e.g., ZIKV) also trigger ocular inflamma-
tion (e.g., conjunctivitis, uveitis) and can be detected in the vit-
reous humor in rare cases (de Paula Freitas et al., 2017; Heck
et al., 2017; Kodati et al., 2017; Miner et al., 2016b). Addition-
ally, SARS-CoV-2 RNA has been detected in tears (Fang
et al., 2020; Karimi et al., 2020; Wu et al., 2020), and it
has been widely hypothesized that the eye, including the
cornea and conjunctiva, may serve as a route of entry for
SARS-CoV-2.
ZIKV does not replicate efficiently in immunocompetent mice
(Grant et al., 2016). Therefore, in our prior studies of ZIKV path-
ogenesis in the eye, it was necessary to study immunodeficient
Ifnar1/ animals (Miner et al., 2016b). We found that ZIKV in-
vades and replicates in the eyes of mice and that ZIKV RNA
was detectable in the cornea. However, we did not test whether
viral RNA found in the cornea was associated with infectious vi-
rus (Miner et al., 2016b). Subsequently, humans with ZIKV infec-
tion were reported to have ZIKV RNA and infectious ZIKV in
conjunctival swabs (Sun et al., 2017). ZIKV-induced uveitis and
conjunctivitis also occur in humans (de Paula Freitas et al.,
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2017; Kodati et al., 2017), suggesting that ZIKV can infect the eye
and cause ocular inflammation.
Here, we report that HSV-1 and ZIKV, but not SARS-CoV-2,
can replicate in human corneal explants. We found that type III
IFN (also known as IFN-l) and its receptor (IFNlR1) are ex-
pressed and functional in the human and mouse cornea. Using
a model of corneal transplantation in mice, we found that ZIKV
is only rarely transmitted by corneal transplantation in immuno-
deficient AG129 mice that lack the type I and type II IFN recep-
tors. This led us to hypothesize that IFN-lmay play a role in con-
trolling infection in the cornea. Indeed, we found that IFN-l and
IFNlR1 are expressed within and exhibit antiviral activity in
cultured human corneal explants. Furthermore, we found that
antiviral ISGs are constitutively upregulated in the epithelium of
human corneal explants and that treatment of mice with IFN-l
eye drops causes IFNlR1-dependent upregulation of antiviral
ISGs. Blockade of IFNlR1 in human corneal explants led to
enhanced replication of ZIKV and a10-fold increase in replica-
tion of HSV-1. In contrast, blockade of IFNlR1 did not result in
permissiveness of human corneal tissue to infection with
SARS-CoV-2. Thus, IFNlR1 restricts HSV-1 and ZIKV infection
in human corneal tissue. Furthermore, resistance of human
corneal tissue to SARS-CoV-2 infection is likely regulated by a
distinct antiviral pathway.
RESULTS AND DISCUSSION
ZIKV Transmission by Corneal Transplantation in Mice
Althoughwe previously detected ZIKVRNA inmouse corneas af-
ter subcutaneous inoculation, we did not test whether this viral
RNA represents infectious viral particles (Miner et al., 2016b).
AG129 mice, which lack both type I and type II IFN receptors
(van den Broek et al., 1995), are highly susceptible to ZIKV.
Indeed, even a single infectious particle is sufficient to cause
death in AG129 animals (Aliota et al., 2016). To test whether in-
fectious virus was present in mouse corneas following subcu-
taneous inoculation with ZIKV, we intraperitoneally inoculated
8-week-old AG129 animals with corneal homogenates after
microdissection of eyes from Ifnar1/ mice 7 days after subcu-
taneous inoculation with a clinical ZIKV isolate from Brazil. Three
of 11 AG129 mice inoculated with corneal homogenates devel-
oped ZIKV encephalitis and succumbed to infection (Figure 1A).
Thus, infectious ZIKV is associated with the corneas of Ifnar1/
mice following subcutaneous footpad inoculation.
Transmission of viruses by solid organ transplantation is a ma-
jor clinical concern that requires careful safeguards (Heck et al.,
2017; Nogueira et al., 2017). Furthermore, ZIKV transmission via
solid organ transplantation has been previously described in hu-
mans (Nogueira et al., 2017). To test whether ZIKV transmission
might be possible after corneal transplantation in animals, we
performed corneal transplantation experiments in AG129 mice.
Donor AG129 mice were subcutaneously inoculated with 1,000
FFU of ZIKV and euthanized 7 days after infection, followed by
tissue harvesting and microdissection of corneas. We confirmed
the presence of 105–106 FFU equivalents of ZIKV in the posterior
eye, liver, spleen, brain, kidney, and serum of infected donor an-
imals (Figure 1B). The donor corneas were washed extensively in
PBS and subsequently transplanted into naive AG129 recipient
mice. Six days after transplantation, recipient mice were eutha-
nized, and ZIKV RNA in multiple organs was quantitated using
qRT-PCR. Although viral RNA was detectable in multiple organs
at low levels in all recipient animals, severe infection of multiple
organs occurred in just one of the six recipient mice (Figure 1C).
Thus, ZIKV can cause systemic infection following corneal trans-
plantation in mice, but this occurs infrequently. Next, to evaluate
whether ZIKV remains stable and infectious in cornea storage
medium, we tested the stability of ZIKV in Optisol. ZIKV (6 3
105 FFU per tube) was stored in Optisol at 4C for 1 month, fol-
lowed by quantitation of infectious virus by focus forming assay.
By day 28,more than 103 FFU/mL of infectious ZIKVwas still pre-
sent under these conditions (Figure 1D), indicating that infectious
ZIKV can persist in conditions typical for storage of human donor
corneas.
ZIKV Infects the Human Corneal Epithelium but Does
Not Replicate Efficiently in Human Corneal Explants
To test whether ZIKV replicates in human corneal tissue, we per-
formed viral growth curve studies by inoculating human corneal
explants with 33 106 FFU/mL of ZIKV, followed by focus forming
assays over the course of 72 h (Figures 1E and F). ZIKV repli-
cated inefficiently in just one of three human cornea donor sam-
ples (Figure 1E), suggesting that the human cornea is somewhat
resistant to ZIKV infection. To define ZIKV tropism in the human
cornea, we performed RNA in situ hybridization (ISH) of ZIKV-in-
fected corneal explants 24 h after infection (Figure 1F). Histolog-
ical analysis revealed that ZIKV preferentially infects a small
number of corneal epithelial cells, without appreciably pene-
trating into deeper layers of the human cornea. We hypothesized
that constitutive IFN signalingmay be controlling viral infection in
the human corneal explants, so we measured IFN and ISG
expression in human corneal explants cultured in the absence
of virus. We observed expression of type III IFNs (IFNL1,
IFNL2) and IFIT1 (an ISG) mRNA, even in the absence of infection
(Figure 1G). As IFNL1 and IFNL2 expression is regulated by IRF3,
we hypothesized that either cytosolic DNA- or RNA-sensing
pathways may upregulate IFNL1 or IFNL2 via IRF3 downstream
of TBK1 signaling induced by endogenous retroelements. To test
this hypothesis, we treated corneas with an antiretroviral drug
(AZT) or TBK1 inhibitor (MRT67307), but neither of these inhibi-
tors affected basal expression of IFNL1 or IFNL2 (Figure S1),
suggesting that basal expression of IFNL1 and IFNL2 are regu-
lated independently of TBK1-mediated phosphorylation of IRF3.
Treatment of Mouse Corneal Explants with IFN-l
Upregulates Expression of ISGs
As IFN-l restricts infection at some barrier surfaces, we
reasoned that topical treatment with IFN-l eye drops might up-
regulate ISG expression inmice specifically in the cornea. To test
this hypothesis, we administered two doses of 1 mg topical re-
combinant IFN-l eye drops or PBS control to wild-type (WT)
and Ifnlr1/ mice, followed by microdissection of corneas and
quantitation of ISG expression using qRT-PCR. In WT mice,
but not Ifnlr1/ mice, treatment with IFN-l caused upregulation
of multiple ISGs, including Ifit2, Ifit3, and Isg15, but not Ifi27 (Fig-
ures 2A–2E). These results indicate that topical IFN-l induces




antiviral gene expression in the mouse cornea under physiolog-
ical conditions.
To determine whether IFN-l promotes antiviral immunity in the
human cornea, we began by performing RNA ISH and discov-
ered that IFNlR1 is expressed specifically in the human corneal
epithelium (Figure 3A), which are target cells for viruses known to
cause corneal pathology, including HSV-1 (Oh, 1976). Treatment
of human corneal explants with 43 104 U/mL of IFN-l for 6 h led
to a 2-fold increase in IFNLR1 mRNA (Figure 3B), as well as a
50-fold increase in expression of IFIT1 and a25-fold increase
in IFIT2 (Figures 3C and 3D). IFI27 and IRF7 also were upregu-
lated by approximately 3-fold to 5-fold after treatment with
IFN-l (Figures 3E and 3F). Thus, IFN-l induces expression of
antiviral ISGs in the human cornea.
To test whether IFN-l protects against infection with ZIKV, we
pre-treated human donor corneas for 1 h with either anti-IFNlR1
monoclonal antibody (mAb) or a control mAb (Kotenko et al.,
2003) and then performed viral growth curve analysis as
described in Figure 1. In two of five samples, blockade of the
IFNlR1 resulted in an approximately 100-fold greater ZIKV repli-
cation (Figure 3G). However, in other growth curve experiments
of ZIKV in the human cornea, viral replication was not detected
(data not shown). This suggests that the role of IFNlR1 in con-
trolling ZIKV infection is variable in distinct donors.
Next, as HSV-1 is well established as a corneal pathogen in
humans, we inoculated human corneal explants with 106 PFU/
mL of HSV-1 in the presence of the same blocking anti-IFNlR1
mAb or control mAb (Kotenko et al., 2003). This led to consis-
tently enhanced replication of HSV-1 in all infected human donor
samples, with approximately 10-fold higher levels of infectious
virus by 72 h after infection (6.1 3 104 PFU/mL in anti-IFNlR1
treated corneas versus 6.3 3 103 PFU/mL in control mAb-
treated corneas, p < 0.005) (Figure 3H). HSV-1 blocks the type
I IFN response in order to facilitate viral replication (Yuan et al.,
2018), so we reasoned that HSV-1 may similarly antagonize
IFN-l production or signaling. Quantitation of IFNL1 and IFNL2
mRNA with and without HSV-1 revealed that HSV-1 infection re-
duces expression of IFNL2 within the first 24 h after infection
Figure 1. ZIKV Can Be Transmitted via Corneal Transplantation in AG129 Mice but Infects Human Corneal Explants Inefficiently
(A) Survival of AG129mice inoculated with Ifnar1/ corneal homogenates 7 days after subcutaneous inoculation with ZIKV (n = 11) or uninfected Ifnar1/ cornea
control homogenates (n = 4).
(B andC) ZIKVmRNA expression in tissueswas quantitated using qRT-PCR. Tissues were harvested from cornea donors (n = 2) and recipient (n = 6)mice on days
6 and 7 after infection.
(D) ZIKV (63 105 FFU) was stored in cornea storage medium (Optisol) at 4C for 28 days. Infectious virus was measured by focus forming assay at the indicated
time points.
(E) Human donor corneas (n = 4 technical replicates per donor from three independent donor corneas) were inoculated with 33 106 FFU/mL of ZIKV (Brazil strain),
and infectious virus was quantitated at the indicated time points by focus forming assay. Data represent the mean ± SEM.
(F) RNA ISH and histological analysis was performed on uninfected (left panel) and ZIKV-infected (right panel) human corneal explants in order to determine virus
tropism. The black arrow indicates infected corneal epithelial cells.
(G) Baseline expression of IFNL1, IFNL2, and IFIT1wasmeasured using qRT-PCR in three human donor corneas in independent experiments. Data represent the
meanDCT ±SEM relative to expression of GAPDH. Each corneawas sectioned to produce eight technical replicates per experiment (n = 24) from three biological
replicates in independent experiments.




(Figures 3I and 3J). RNA ISH demonstrated that IFNL1 was ex-
pressed primarily within the corneal epithelial cells, similar to
what was observed for the IFNLR1 (Figure 3K). Thus, IFN-l
and IFNlR1 are expressed in the human corneal epithelium,
and signaling through IFNlR1 restricts replication of HSV-1 in
human corneal explants.
It has been widely speculated that SARS-CoV-2may infect the
eye (Xia et al., 2020), although it is unusual for patients with
SARS-CoV-2 to develop ocular symptoms. The possibility of
corneal infection is supported by the fact that ACE2, a receptor
for SARS-CoV-2, is highly expressed in the human corneal
epithelium (Collin et al., 2020; Zhou et al., 2020). Therefore, we
tested whether a clinical isolate of SARS-CoV-2 could replicate
in human corneal tissue. However, we detected no evidence of
SARS-CoV-2 replication using qRT-PCR in seven independent
donor samples. The same negative results were obtained by pla-
que assay (data not shown). Positive controls were used in all ex-
periments, including conformation that HSV-1 could replicate in
portions of the very same donor corneas. Unlike what was
observed with HSV-1 and ZIKV, blockade of IFNlR1 did not
make the human corneal tissue more permissive to infection
with SARS-CoV-2 (Figure 3L). As the corneal explants also
include a small amount of conjunctival tissue, our findings sug-
gest that the human cornea and conjunctiva may not support
infection with SARS-CoV-2 and that antiviral immunity against
SARS-CoV-2 in the cornea is mediated by a pathway other
than IFNlR1 signaling. Nevertheless, further study of human pa-
tient and autopsy samples will be necessary to confirm that the
human cornea and conjunctiva are resistant to infection with
SARS-CoV-2.
Studies of antiviral immunity at barrier surfaces previously
demonstrated that IFN-l regulates permeability of the blood-
brain barrier (Lazear et al., 2015), protects the gut against enteric
virus infection (Nice et al., 2015), and promotes antiviral immunity
at the placental barrier (Jagger et al., 2017). We discovered that
the human corneal barrier also is a site of action for IFN-l and
IFNlR1 and that IFNlR1 signaling inhibits replication of HSV-1
in human corneal explants. Additionally, we found that IFN-l
eye drops upregulate antiviral ISGs inWT but not in Ifnlr1/ cor-
neas in mice, revealing a capacity of IFN-l to exert a topical ef-
fect. As the IFN-l antiviral pathway was not previously described
to have activity in the human eye, our discoveries may lead to
further exploration of the role of IFN-l and IFNlR1 during ocular
infection and inflammatory eye disease pathogenesis in humans.
IFNlR1 signaling likely occurs in corneal epithelial cells. In
support of this conclusion, we detected expression of IFNLR1
and IFNL1 mRNA within the human corneal epithelium. Corneal
epithelial cells also are a primary target for HSV-1 infection of
the cornea (Farooq and Shukla, 2012; Oh, 1976), and we found
that blockade of IFNlR1 signaling led to more severe HSV-1
infection of human corneal explants, indicating that IFN-l
signaling in the cornea mediates protection against herpesvirus
infection. As our experiments only tested the role of IFN-l during
infection of human corneas, future studies in mice may allow us
to examine whether similar anti-viral effects occur in animal
models. Although prior studies of the mouse cornea have not
examined the effect of IFNlR1 blockade or genetic deletion,
treatment of mice with recombinant IL-28A (IFN-l) affected im-
mune responses and infection in a model of stromal keratitis
(Jaggi et al., 2018), providing further support for the idea that
IFN-l is relevant in the eyes of mice. Future studies in mouse
models using Cre-lox alleles for IFNlR1 and IFN-l2/3 will allow
us to define the cell type-specific effects of IFN-l and IFNlR1
during corneal inflammation and infection.
We previously found that ZIKV infects the corneas of mice lack-
ing IFNAR1 (Ifnar1/ mice) (Miner et al., 2016b). Although we
confirmed that ZIKV can be transmitted by corneal transplantation
in immunodeficient mice, severe systemic infection occurred in
only one of six animals. Furthermore, ZIKV replicated inefficiently
in human corneal explants, suggesting that the cornea is unlikely
to be a major target of ZIKV infection despite what has been
Figure 2. IFN-l Eye Drops Induce ISG Expression in WT but Not
Ifnlr1/ Corneas
Adult WT and Ifnlr1/ animals were treated with recombinant mouse IFN-l
(1 mg) in 10 mL PBS or PBS vehicle control. Mice were treated again 3 h later
and then euthanized for corneal microdissection 6 h after the first treatment.
Corneas were homogenized in PBS, and mRNA was isolated for gene
expression analysis. ISG expression in corneas was quantitated using qRT-
PCR (n = 3–5 mice per group). Results represent the mean ± SEM of data
pooled from two independent experiments. Results were analyzed using the
Mann-Whitney test. *p < 0.05.




observed in animal models. Nevertheless, ZIKV RNA has previ-
ously been detected in the vitreous humor of a human donor sam-
ple (Heck et al., 2017) and in human conjunctival swabs (Sun et al.,
2017), suggesting that ZIKV can occasionally be harbored in or
associated with human corneas. As even one infection occurring
as a consequence of corneal transplantation could be harmful,
there is a need to continue screening donated corneas for arbovi-
ruses, especially in the context of virus outbreaks.
Figure 3. The IFN-l Receptor (IFNlR1) Regulates Antiviral ISG Expression and Restricts HSV-1 Growth in Human Corneal Explants
(A) RNA ISH and histological analysis were performed on human donor corneas to determine IFNLR1mRNA expression in the corneal epithelium. Panels shown
are positive control housekeeping gene (left), negative control probe (middle), and IFNLR1 (right). Scale bar, 10 mm. Data are representative of three independent
experiments with unique donor corneas. Black arrows indicate positive staining of cells for IFNLR1.
(B–F) Human donor corneas were treated with IFN-l or PBS vehicle control, and ISG expression from human corneal explants was quantitated using qRT-PCR.
Data represent the mean ± SEM of 12 samples, including 4 cornea segments per donor from 3 donor corneas. Results were pooled from two independent
experiments.
(G) ZIKV replication in a representative human donor cornea sample treated with anti-IFNlR1 or isotype control antibody. Infectious units of ZIKV were quan-
titated by focus forming assay. ZIKV replicated in only 2 of 5 human cornea samples under these conditions. Results were analyzed using two-way ANOVA.
(H) HSV-1 replication in human donor corneas treated with anti-IFNlR1 or isotype control antibody. Infectious units of HSV-1 were quantitated at the 3 h eclipse
phase and every 24 h thereafter by plaque assay. Data represent the mean ± SEM of n = 12 replicates, including 4 technical replicates per group from 3 corneas.
Results in (H) were pooled from three independent experiments and were analyzed using two-way ANOVA.
(I and J) IFNL1 and IFNL2 mRNA expression levels were quantitated using qRT-PCR 24 h after infection with HSV-1. Data represent the mean ± SEM of mock-
infected (n = 3) and infected (n = 3) human donor corneas with 4 cornea segments per donor in two independent experiments.
(K) RNA ISH and histological analysis were performed on human donor corneas to determine IFNL1mRNA expression in the cornea. Scale bar, 10 mm. Data are
representative of 10 samples from seven independent donors. Samples from two donors repeatedly did not stain for positive control (or target) and were
excluded. Black arrows indicate positive staining of cells for IFNL1.
(L) SARS-CoV-2 replication in human donor corneas samples treated with anti-IFNlR1 or isotype control antibody. SARS-CoV-2 mRNA expression was
measured using qRT-PCR. Data represent themean ± SEMof n = 7–11 replicates, with two to four technical replicates per group from 3 donor corneas. Results in
(L) were pooled from two independent experiments and were analyzed by two-way ANOVA.
Results in (B)–(F), (I), and (J) were pooled from two independent experiments and were analyzed using the Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001. See also Figure S1.




Wediscovered that HSV-1 has the capacity to antagonize pro-
duction of IFN-l2 in the human cornea, implying that immune
evasion of IFN-lmay contribute to HSV-1 disease pathogenesis.
Prior cell culture studies demonstrated that IFN-l inhibits HSV-1
replication in astrocytes and neurons by stimulating the expres-
sion of endogenous type I IFN and ISGs (Li et al., 2011).
Our study confirms that IFNlR1 signaling restricts HSV-1 in hu-
man samples and also reveals a role for this pathway in the hu-
man eye.
In addition to expression in corneal epithelial cells, IFNlR1 is
expressed on neutrophils, which are known to infiltrate and dam-
age the cornea during HSV-1 infection (Thomas et al., 1997).
Remarkably, in addition to controlling infection, IFN-l can
ameliorate inflammatory responses mediated by neutrophils
(Blazek et al., 2015). Thus, our work may inform further studies
of disease pathogenesis in animals, as well as therapies target-
ing IFNlR1. This may eventually lead to prophylactic or thera-
peutic administration of IFN-l to control infection or to dampen
destructive immune responses in the cornea.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse anti-human interferon lambda receptor 1
neutralizing mAb
PBL assay science Cat# 21885-1 Unable to locate RRID
Mouse IgG1 kappa isotype control mAb Sigma-Aldrich Cat# M7894, RRID:AB_1163632
Bacterial and Virus Strains
Herpes simplex virus-1 strain 17+ Bertke et al., 2013 N/A
Zika virus, strain Paraiba 2015 (Brazil, 2015) Magnani et al., 2018 N/A
SARS-CoV-2 (strain 2019 n-CoV/USA_WA1/2020) CDC/BEI Resources NR52281
Biological Samples
Human corneas Mid-America Transplant Institute N/A
Chemicals, Peptides, and Recombinant Proteins
Recombinant Human IL-29/IFN Lambda 1, HCE PBL assay science Cat# 11725-1
Recombinant Mouse IL-28B/IFN Lambda 3 PBL assay science Cat# 12820-1
Critical Commercial Assays
RNeasy Mini Kit QIAGEN Cat# 74104
TaqMan RNA-to-Ct 1-Step Kit ThermoFisher Cat# 4392653
Experimental Models: Cell Lines
Vero CCL81 cells ATCC CCL81; RRID: CVCL_0059
Vero E6 cells ATCC CRL-1586; RRID: CVCL_0574
Experimental Models: Organisms/Strains
Mouse: Ifnar1/ Jackson Laboratory Cat# JAX:032048, RRID:
IMSR_JAX:032048
Mouse: AG129 Marshall BioResources AG129
Mouse: Ifnlr1/ Baldridge et al., 2017 N/A
Oligonucleotides
SARS-CoV-2 N F: 50 -ATGCTGCAATCGTGCTACAA-3 Hassan et al., 2020 N/A
SARS-CoV-2 N R: 50 -GACTGCCGCCTCTGCTC-30 Hassan et al., 2020 N/A
SARS-CoV-2 N Probe: 50 -/56-FAM/TCAAGGAAC/ZEN/
AACATTGCCAA/3IABkFQ/-30
Hassan et al., 2020 N/A
RNAscope Probe- V-ZIKV Advanced Cell Diagnostics Cat# 467771
RNAscope Probe- Hs-IFNLR1 Advanced Cell Diagnostics Cat# 494771
RNAscope Probe- Hs-IFNL1 Advanced Cell Diagnostics Cat# 412341
IFNL1 PrimeTime qPCR Assay Integrated DNA Technologies Hs.PT.56a.21113836.g
IFNL2 PrimeTime qPCR Assay Integrated DNA Technologies Hs.PT.56a.38564463
IFNLR1 PrimeTime qPCR Assay Integrated DNA Technologies Hs00417120_m1
IFIT1 PrimeTime qPCR Assay Integrated DNA Technologies Hs.PT.56a.20769090.g
IFIT2 PrimeTime qPCR Assay Integrated DNA Technologies Hs.PT.58.1099131
IRF7 PrimeTime qPCR Assay Integrated DNA Technologies Hs.PT.58.24613215.g
IFI27 PrimeTime qPCR Assay ThermoFisher Hs01086373_g1
GAPDH PrimeTime qPCR Assay Integrated DNA Technologies Hs.PT.39a.22214936
Ifit1 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.32674307
Ifit2 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.45910930.g
Ifitm3 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.56a.29591636
Irf7 PrimeTime qPCR Assay ThermoFisher Mm00516793
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jonathan
J. Miner (miner@wustl.edu).
Materials Availability
This study did not generate new unique reagents. Commercially available reagents are indicated in the Key Resources Table.
Data Availability
This study did not generate/analyze datasets/code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Vero CCL81 cells were used to passage and titrate ZIKV and HSV-1. Vero E6 cells were used to passage and titrate SARS-CoV-2.
Both cell lines were cultured in Dulbecco’sModified EagleMedium (DMEM) supplementedwith 10% fetal bovine serum (FBS), 100U/
mL penicillin/streptomycin, 10mM HEPES buffer, 1mM sodium pyruvate, and 1 x non-essential amino acids. Cell lines were kept at
37C in a humidified atmosphere at 5% CO2.
Viruses
ZIKV (Brazil strain) was a passage 3 stock derived from a clinical isolate from Paraiba, Brazil (Magnani et al., 2018). Viral titers were
measured by focus forming assay as previously described (Miner et al., 2016a). ZIKVwas passaged in Vero CCL81 cells. HSV-1 strain
17+ also was passaged in Vero CCL81 cells and provided by T. Margolis (Washington University, Saint Louis, MO) (Bertke et al.,
2013). SARS-CoV-2 (2019 n-CoV/USA_WA1/2020) was obtained from the Centers for Disease Control and Prevention (gift of Natalie
Thornburg) and was passaged in Vero CCL81 cells. SARS-CoV-2 titers were measured by qRT-PCR and by infectious plaque assay
in Vero E6 (CRL-1586) cells (Hassan et al., 2020).
Mouse experiments
All protocols for animal studies were approved by the Institutional Animal Care and Use Committees at the Washington Univer-
sity School of Medicine (assurance no. A-3381-01). Mice were housed in specific pathogen-free mouse facilities at the Wash-
ington University School of Medicine. AG129 and Ifnar1/ mice were purchased from the Jackson laboratory. Ifnlr1/ mice
were previously described (Baldridge et al., 2017) and provided by M.T. Baldridge (Washington University, Saint Louis, MO).
Power analysis was conducted for Institutional Animal Care and Use Committee-approved in vivo studies in order to determine
the number of animals needed per experimental group. At least two independent experiments were conducted to replicate find-
ings. No outliers were excluded from analyses. Approximately equal numbers of both sexes were studied. The age and number
of animals used for each experiment is listed in the figure legends.
Ifnar1/mice were inoculated with 103 FFU of a pathogenic clinical ZIKV isolate fromBrazil via subcutaneous footpad inoculation.
Corneas were harvested 7 days post-inoculation and homogenized. Eight-week-old AG129 mice were then inoculated intraperito-
neally with corneal homogenates in 100 mL of PBS or mock-infected cornea control samples. Mice were monitored for 30 days to
assess survival. For corneal transplantation studies, AG129 mice were inoculated subcutaneously with 103 FFU of ZIKV. Donor
mice were euthanized 7 days post-infection and corneas weremicrodissected andwashed repeatedly in PBS, and then transplanted
to AG129 recipients as previously described (He et al., 1991). Recipient mice were euthanized 7 days post-transplantation, followed
by dissection of tissues, homogenization, and quantitation of viral RNA by qRT-PCR using virus-specific primers and probes as pre-
viously described (Miner et al., 2016a).
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Isg15 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.41476392
Ifi27 PrimeTime qPCR Assay ThermoFisher Mm00835449_g1
Gapdh PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.39a.1
Software and Algorithms
GraphPad Prism 8 GraphPad https://www.graphpad.com





Human cornea infections and virus stability measurements
De-identified human donor corneas were obtained fromMid-America Transplant Institute and consisted of cornea samples found to
be unsuitable for transplant. Experiments were performed on a total of 25 donor corneas (ages of donors were 20-, 21-, 23-, 28-, 32-,
35-, 40-, 40-, 40-, 40-, 40-, 51-, 53-, 55-, 55-, 55-, 56-, 56-, 64-, 66-, 66-, 67-, 67-, 69-, and 74-years-old) fromboth genders. This work
was IRB-exempt since it involved de-identified human tissue from deceased organ donors.
For ZIKV replication studies, human corneal explants were inoculated with 33 106 FFU/ml of ZIKV. Corneas were washed 6 times
in 50 mL of PBS, and growth curve analysis was performed by focus forming assay as previously described (Miner et al., 2016a). For
growth curve experiments examining HSV-1, ZIKV, and SARS-CoV-2 replication in the presence and absence of IFNlR1 blockade,
anti-IFNlR1mAb (PBL assay science, catalog # 21885-1) and isotype control antibody (Cat# M7894, RRID:AB_1163632), were used
at a concentration of 10 mg/ml with fresh antibody introduced every 24 hours. In 2 of 5 samples, the initial HSV-1 infection failed, and
so these samples were excluded. For SARS-CoV-2 infection studies, the inoculation dose was 13 106 PFU/ml, followed by washing
steps as described for HSV-1 and ZIKV. Seven human donor samples were evaluated for SARS-CoV-2 infection, three of which were
evaluated in the presence of anti-IFNlR1 mAb or control mAb. Treatment of human corneas with recombinant human IL-29/IFNL1
(PBL assay science, catalog #11725-1) was performed at a concentration of 4.35 x104 U/ml for 6 hours. Cornea storage medium
(OptisolTM) was obtained from the Washington University Department of Ophthalmology. Persistence of infectious ZIKV in cornea
storage medium was assessed by introducing 6 3 105 FFU of ZIKV into cornea storage medium at 4C. Levels of infectious ZIKV
were quantitated by focus forming assay every two days for 28 days.
RNA in situ hybridization (ISH) and ISG expression
Human corneas were sectioned and RNA ISH was performed with RNAscope 2.5 (Advanced Cell Diagnostics) according to the
manufacturer’s instructions, using virus-specific probes for ZIKV as previously described (Miner et al., 2016b). To visualize IFNLR1
and IFNL1 mRNA expression in uninfected human corneas, samples were sectioned and RNA ISH was performed with specific
probes for the IFNLR1 gene using ACD Bio probe number 494771 RNAscope  2.5 (Advanced Cell Diagnostics) Probe-Hs-IFNLR1.
RNA Scope 2.5 HD red was used per manufacturer’s instructions.
Gene expression analysis and IFN-l treatment of mice
Total RNA was extracted from microdissected corneal homogenates using the RNAeasy kit (QIAGEN) according to the manufac-
turer’s instructions. To test whether ISG upregulation was dependent on IFNlR1, we administered two doses of 1 mg of mouse
IL28B/IFN-l3 in PBS (PBL assay science, catalog #12820-1) or PBS control to WT and Ifnlr1/ mice. Doses were 3 hours apart.
Three hours after the 2nd treatment, mice were euthanized and corneas were harvested. qRT-PCR was performed using TaqMan
RNA-to-Ct 1-Step kit (Applied Biosystems) according to the manufacturer’s instructions. Results were calculated using the DDCt
method, normalizing to GAPDH. Primers were obtained from Integrated Device Technology (IDT).
Human cornea inhibitor experiments
Human corneas were cut into 8 pieces per cornea and placed individually into 24-well plates with 0.3mLmedia containing inhibitor or
vehicle control. Inhibitors used were 10mMMRT67307 (Selleckchem S7948) and 50mM azidothymidine (R&D Systems 4150/50). For
each donor, 4 pieces from one cornea were incubated with the inhibitor and the remaining 4 pieces with vehicle for 6 hours at 37C.
Cornea pieces were stored at 80C. After thawing, pieces were transferred to gentleMACS C tubes containing 1mL DMEM + 2%
FCS + collagenase (Sigma, C0130) + dispase I (Sigma D4818) and incubated with shaking at 37C for 2 hours. Tissues were disso-
ciated using a gentleMACS Dissociator (Miltenyi). Dissociated tissue was then filtered over 70mmmesh filters, centrifuged at 300 x g
for 10min at 4C, and pellets were resuspended in 250uL RLT buffer (QIAGEN). RNAwas isolated using the RNeasymini kit (QIAGEN)
according to themanufacturer’s protocol. qRT-PCRwas performed using a TaqMan RNA-to-CT 1-step kit (Applied Biosystems). Re-
sults were calculated using the threshold cycle (DDCT) method, normalizing to GAPDH. Primers were obtained from Integrated De-
vice Technology, Inc. (IDT).
QUANTIFICATION AND STATISTICAL ANALYSIS
All data were analyzed using GraphPad Prism software by Mann-Whitney test or two-way ANOVA, as specified in the figure legends.
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Figure S1. Treatment with inhibitors of TBK1 or reverse transcriptase does not impact 
expression of IFNL1 or IFNL2 in the human cornea. Related to Figure 3. (A-D) Human donor 
corneas were treated with TBK1 inhibitor (MRT 67307), an anti-retroviral drug (AZT), or DMSO 
vehicle control for 6 hours, and then IFNL1 and IFNL2 mRNA expression was quantitated by qRT-
PCR. Data represent the mean +/- SEM of human donor corneas (n = 3) with 4 cornea segments 
per condition pooled from 2 independent experiments. Results were analyzed by Mann-Whitney 
test. 
 
